GLP-1, or glucagon-like peptide-1 drugs, are a synthetic version of the body’s naturally occurring hormone that reduces appetite and slows down the rate at which food leaves the stomach. Originally developed to treat diabetes, GLP-1s’ popularity has skyrocketed because of their use for weight loss. In 2023, GLP-1s alone accounted for nearly 7% of the Read More
In this article, we will look at ISO 31030 and discuss how companies can use this benchmark to review their own risk management strategies for domestic and international travel. Business travel has changed considerably since the pandemic. Whether it’s heightened awareness about illness or increased threats from civil unrest and natural disasters, companies should reassess Read More
This case study shows the benefits of having an independent Stop Loss carrier focused onthe right care at the right price.
This story demonstrates the success that Berkley Edge can have in helping control high-dollar claims.
Read our March 2024 update on the cell and gene therapy pipeline, with an in-depth look at Casgevy
U.S. employees are facing new challenges while on the road, according to a new survey sponsored by Berkley Accident and Health.
This case study shows the benefits of having an independent Stop Loss carrier focused on the right care at the right price.
Read our October 2023 report on the cell and gene therapy market
Read our April 2023 report on the cell and gene therapy market
Berkley Accident and Health shows the benefits of having a Provider Excess insurer that not only assists clients with high-dollar claims, but also focuses on the right care at the right price.